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Background: Doxorubicin (DOX) is an effective antineoplastic drug; however, clinical use of DOX is limited by its
dose-dependent cardiotoxicity. It is well known that reactive oxygen species (ROS) play a vital role in the
pathological process of DOX-induced cardiotoxicity. For this study, we evaluated the protective effects of
guggulsterone (GS), a steroid obtained from myrrh, to determine its preliminary mechanisms in defending against
DOX-induced cytotoxicity in H9C2 cells.
Methods: In this study, we used a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay,
lactate dehydrogenase (LDH) release measurements, and Hoechst 33258 staining to evaluate the protective effect
of GS against DOX-induced cytotoxicity in H9C2 cells. In addition, we observed the immunofluorescence of
intracellular ROS and measured lipid peroxidation, caspase-3 activity, and apoptosis-related proteins by using
Western blotting.
Results: The MTT assay and LDH release showed that treatment using GS (1–30 μM) did not cause cytotoxicity.
Furthermore, GS inhibited DOX (1 μM)-induced cytotoxicity in a concentration-dependent manner. Hoechst 33258
staining showed that GS significantly reduced DOX-induced apoptosis and cell death. Using GS at a dose of
10–30 μM significantly reduced intracellular ROS and the formation of MDA in the supernatant of DOX-treated
H9C2 cells and suppressed caspase-3 activity to reference levels. In immunoblot analysis, pretreatment using GS
significantly reversed DOX-induced decrease of PARP, caspase-3 and bcl-2, and increase of bax, cytochrome C
release, cleaved-PARP and cleaved-caspase-3. In addition, the properties of DOX-induced cancer cell (DLD-1 cells)
death did not interfere when combined GS and DOX.
Conclusion: These data provide considerable evidence that GS could serve as a novel cardioprotective agent
against DOX-induced cardiotoxicity.
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Doxorubicin (DOX), a member of the anthracycline
class of chemotherapeutic drugs, is a potent antineoplas-
tic drug that has exhibited a wide spectrum of antitumor
activity including in leukemia, lymphomas, soft tissue
sarcomas, and breast cancer for several decades. Despite
the efficacy of DOX, its use has been limited by the
dose-dependent cardiotoxicity associated with acute and
chronic treatments in anticancer therapy [1-3]. Both
acute and chronic DOX-induced cardiotoxicity may
cause cardiac dysfunction or cardiomyopathy, and may
ultimately lead to rigorous heart failure and death [3,4].
Previous studies have suggested that one mechanism
responsible for DOX cardiotoxicity is the formation of
reactive oxygen species (ROS) [5,6], which can harm
membrane lipids and other cellular components, lead-
ing to cardiomyocyte apoptosis and death [7]. Certain
antioxidants have been examined to reduce ROS forma-
tion, but many have demonstrated only a limited cardio-
protective effect or have other side effects [8,9].
Guggulsterone (GS) is a steroid compound that has
been isolated from myrrh [10,11]; the structure of
which is shown in Figure 1 [12]. In 1972, two isomer
derivatives, Z-GS and E-GS, were identified in Commi-
phora mukul (containing 4.50% (Z)-isomer and 1.42%
(E)-isomer) [13] as antagonist ligands for the bile acid
receptor farnesoid X receptor and as active ingredients
responsible for hypolipidemic activity [14,15]. During a
10-year period, myrrh was examined to treat various
conditions, such as rheumatism, atherosclerosis, hyper-
cholesterolemia, and obesity [16]. Both GS isomers were
demonstrated to suppress LPS-induced inflammation
by inhibiting IκB-α degradation and NF-κB activation
[17,18]. GS was mediated (possibly by activating pro-
tein-1) to upregulate the expression of the bile salt ex-
port pump [16]. In addition, GS was reported to protect
cardiac and neuronal damages in animal models [19].
However, no research has yet been conducted on the
use of GS in protecting against DOX-induced car-
diotoxicity. This study is the first to evaluate the pro-
tective effects of GS to determine the preliminaryFigure 1 Structure of Z-guggulsterone [trans-4,17(20)-pregnadiene-3,mechanisms of defending against DOX-induced cyto-
toxicity in H9C2 cells.Methods
Chemicals
Dulbecco’s Modified Eagle’s Medium, an RPMI 1640
medium, fetal bovine serum, penicillin/streptomycin,
and medium supplements were purchased from Life
Technologies (Gibco, Grand Island, NY). Monoclonal
antibodies and a peroxidase-conjugated secondary anti-
body were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). DOX, GS, and other agents were
obtained from Sigma Chemical (St. Louis, MO).Cell culture
All rat cardiac H9C2 myocardial cells, spontaneously
immortalized ventricular rat embryo myoblasts, and
DLD-1 cells (human colon adenocarcinoma) were pur-
chased from the Food Industry Research and Develop-
ment Institute, Taiwan (BCRC). The H9C2 cells were
cultured in DMEM supplemented with 10% fetal bovine
serum at 37°C in 5% CO2, and DLD-1 cells were cul-
tured in the RPMI 1640 medium. The media were chan-
ged every 2–3 d.Cell viability
Sub-confluent cells were trypsinized and seeded onto
96-well plates at a density of 1.5 × 105 cells/ml and incu-
bated for 24 h before treatment. Thereafter, the cells
were exposed to DOX 1 μM for 24 h and then incubated
in a fresh medium with Z-GS at various concentrations
for an additional 24 h. The effects of GS on DOX-
induced cytotoxicity were assessed using the MTT assay,
as previously described [20]. The unwashed dye was
eluted and quantified spectrophotometrically at 550 nm
using a microplate reader. Cell viability was determined
as the percentage of surviving cells compared with that
of the DOX-treated control.16-dione] [12].
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cytotoxicity
GS-induced cytotoxicity leading to plasma membrane
damage was measured using the LDH Cytotoxicity Detec-
tion Kit (Boehringer Mannheim, Mannheim, Germany).
The LDH release assay has been widely used in cytotox-
icity studies [21]. The detailed assay was performed as
previously described [22].
Intracellular ROS
Intracellular ROS induced by DOX was measured using
2’7’-dichlorodihydrofluorescein diacetate (DCFH-DA) as
a fluorescent probe [23]. H9C2 cells were loaded with
DCFH-DA (20 μΜ) for 10 min, followed by 2 washes
with HBSS. Dichlorodihydrofluorescein (DCF) fluores-
cence was detected using a fluorescence spectrophotom-
eter with an excitation of 485 nm and an emission of
520 nm, and the fluorescence image was visualized using
a fluorescence microscope.
Lipid peroxidation
Lipid peroxidation was assayed using the thiobarbituric
acid (TBA) reaction. The amount of thiobarbituric acid
reactive substance (TBARS) was determined using a
standard curve of 1,1,3,3-tetramethoxypropane. The
detailed assay procedure was performed as previously
described [24].
Preparation of total cell lysates and nuclear and cytosolic
extracts
H9C2 cells (5 × 105 cells/well) or DLD-1 cells in 6-well
plates were incubated with or without concentrations of
GS and DOX (1 μM) for 24 h. The total cell lysates
were obtained using a lysis buffer (250 mM Tris–HClFigure 2 Effects of guggulsterone (GS) on the H9C2 cell line. (A) Cells
was determined using an MTT assay, as described in the Materials and Met
results are expressed as mean± S.E. from 3 independent experiments. Aste
(**P < 0.01).(pH 6.8), 1% Triton-100, 0.1% SDS, 1 mM Na3VO4,
1 mM EDTA, 5 mM sodium fluoride, 1 mM PMSF, and
1 mg/ml leupeptin), and cell debris was removed using
a centrifuge at 10 000 × g for 10 min at 4°C and stored
at −80°C until required. The protein content of the cell
lysates was determined using the Bradford assay [25].
Western blot analysis
Equal amounts of cell lysates (30 μg) were electroblotted
onto a nitrocellulose membrane (Millipore, MA), follow-
ing separation using 8%-12% SDS-polyacrylamide gel
electrophoresis. The blot was probed using a primary
antibody against poly (ADP-ribose) polymerase (PARP),
caspase-3, bcl-2, bax, cytochrome C, and β-actin (Santa
Cruz Biochemicals, Santa Cruz, CA). The intensity of
each band was quantified using density analysis software
(MetaMorph Imaging System, Meta Imaging Series 4.5),
and the density ratio represented the relative intensity of
each band against controls in each experiment.
Hoechst 33258 staining
Cells were rinsed twice in 4°C PBS and fixed in 4% for-
maldehyde at 4°C for 10 min. After washing, the cells
were incubated using Hoechst 33258 (5 μg/ml) staining
at room temperature for 10 min in the dark. The cells
were then observed and imaged using a laser scanning
confocal microscope (Bio-Rad MRC-1000, American La-
boratory, USA) with an excitation of 350 nm and an
emission of 460 nm [26].
Caspase-3 activity assay
Caspase-3 activity was determined using the ApoAlert
Caspase Colorimetric Assay kit (Clontech Laboratories,
Inc. USA), according to manufacturer’s protocol.were treated with various concentrations of GS for 24 h. Cell viability
hods section. (B) GS cytotoxicity was analyzed using LDH release. The
risks indicate a significant difference for the control (GS 0 μM)
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The results of all the experiments were expressed as the
mean ± standard error (SE) obtained from the number of
replicate treatments. Data were analyzed using analysis
of variance (ANOVA), followed by Dunn’s post hoc test
for comparison, and P values of < 0.05 were considered
statistically significant.Results
Effects of guggulsterone (GS) on cell viability and
cytotoxicity
The cell survival percentages of H9C2 cells receiving GS
treatment were measured using an MTT assay and an
LDH release assay. As shown in Figure 2A and 2B, the
cells were not significantly injured by GS treatment at
up to 30 μM. These results suggest that GS concentra-
tions were nontoxic to H9C2 cells below 30 μM. Thus,
the cells were treated with GS in concentrations ranging
from 1 to 30 μM for all follow-up experiments.GS protected H9C2 cells from DOX-induced cell death
To determine GS concentrations prevented in DOX-
induced cytotoxicity, we examined the preventive abil-
ities of GS in H9C2 cells at different concentrations.
The results of the MTT assay and LDH release assay
showed that exposure to DOX at a concentration of
1 μM for 24 h caused 25.9% cell death (Figure 3A);
however, no significant reduction of viable cells was
found in 10–30 μM GS-treated cells after 24 h treat-
ment (Figure 3A and 3B). These findings show that
GS at 10–30 μM can reduce DOX-induced cytotoxicity
in H9C2 cells. Microscopic examinations of the cell
cultures showed a reversal of DOX-induced cell deathFigure 3 GS prevention on DOX-induced H9C2 cell death. Cells were in
24 h. The percentages of viable cells were determined using an MTT assay,
expressed as mean±S.E. from 3 independent experiments. *P < 0.05 and **P
indicates a significant difference from the control (GS 0 μM and DOX 0 μMin cell morphology when treated with differing con-
centrations of GS (10, 20, and 30 μM), as shown in
Figure 4.GS relieved oxidative stress induced by DOX in H9C2 cells
As shown in Figure 5, cells exposed to DOX were
significantly brighter than the control cells with nu-
merous highlights, where ROS was concentrated in
dihydroethidium (DHE) staining. By contrast, the red
fluorescence intensity of the cells pretreated with GS
was considerably darker than or nearly as dark as the
control cells. Moreover, the ROS level of the cells
treated with GS alone was nearly the same as that of the
control cells. Nevertheless, we measured the oxidation
of DCFH and lipid peroxidation, which are widely used
markers of intracellular ROS formation, in H9C2 cells
treated for 24 h with 1 μM DOX in the presence or ab-
sence of GS, as shown in Figure 6A and 6B.GS protected against apoptosis of H9C2 cells treated
with DOX
We investigated the effects of GS on DOX-induced
apoptosis in H9C2 cells by using Western blotting.
PARP, caspase-3, and bcl-2 are major types of regula-
tory proteins associated with apoptosis. As shown in
Figure 7A, PARP and bcl-2, two apoptotic suppressors,
were markedly decreased and the cleaved PARP had
increased after treatment with DOX (1 μM) for 24 h. By
contrast, caspase-3 (both the precursor and cleaved
form), a pro-apoptotic protein, was markedly altered
after DOX treatment. However, these effects of DOX-
induced PARP, caspase-3, and bcl-2 were reversed in a
concentration-dependent manner by pretreating withcubated with DOX (1 μM) in the presence and absence of GS for
as described in the Materials and Methods section. The results are
< 0.01 indicate a significant difference from DOX treatment. #P < 0.01
).
Figure 4 Morphology of DOX-induced cell death in H9C2 cells in the presence or absence of GS for 24 h. Cells were viewed using a
video camera (Nikon) attached to a microscope, and the image was projected onto a monitor. Images were obtained with a 200× objective.
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decreased significantly following GS treatment. As
shown in Figure 7B and 7C, the density ratio of PARP
(both the precursor and cleaved form), caspase-3 (both
the precursor and cleaved form), bcl-2, bax, and cyto-
chrome C is represented in quantitative determination.Figure 5 GS relieved the oxidative stress induced by DOX in H9C2 ce
H9C2 cells (original magnification × 200).The protective effects of GS on H9C2 cells were de-
tected using the Hoechst 33258 stained and caspase-3
activity assays. As shown in Figure 8, normal cells were
observed as round-shaped nuclei with homogeneous
fluorescence intensity. DOX induced rapid nuclear
changes of H9C2 with heterogeneous intensity andlls. Staining of intracellular ROS by dihydroethidium (DHE) staining in
Figure 6 Prevention of GS on DOX-induced oxidative stress. Subconfluent H9C2 cells were left untreated or exposed to DOX and co-treated
with GS for 24 h and oxidative stress was evaluated by measuring DCFH oxidation (A) and the amount of TBARS formation (malondialdehyde,
MAD) (B). The results are expressed as mean±S.E. from 3 independent experiments. **P < 0.01 indicates a significant difference from DOX
treatment. ##P < 0.01 indicates a significant difference from the control (GS 0 μM and DOX 0 μM).
Figure 7 Effects of GS on DOX-induced apoptosis-related protein in the cytoplasm of H9C2 cells. (A) Cells (5 × 105 cells/ well) were
pretreated with the indicated concentrations of GS for 2 h before incubation with DOX (1 μM) for 24 h. The proteins (30 μg) of total cell lysates
were analyzed at the expression levels of anti-PARP, caspase-3, bcl-2, bax, and cytosolic lysates that were analyzed for anti-cytochrome C by
Western blotting at 10% SDS-PAGE. β-Actin is the internal standard to confirm equal loading. (B) Quantification of PARP, bcl-2, and caspase-3
expression, and cytochrome C release. (C) Quantification of the cleaved form of PARP and caspase-3, as well as the bax expression. Data are
expressed as mean± S.E. from 3 independent experiments. *P < 0.05, **P < 0.01, and PARP (both the precursor and cleaved form) expression
compared to the DOX treatment alone; #P < 0.05 and ##P < 0.01, and caspase-3 (both the precursor and cleaved form) compared to the DOX
treatment alone; ςP < 0.05 and ςςP < 0.01, and bcl-2 and bax compared to the DOX treatment alone. ξP < 0.05 and ξξP < 0.01, and cytochrome C
compared to the DOX treatment alone.
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Figure 8 The protective effects of GS on H9C2 cells against DOX-induced apoptosis by Hoechst 33258 staining. Fluorescence images of
Hoechst 33258 stained H9C2 cells after a 2 h of exposure to DOX in the absence or presence of GS. Images were obtained using a 200×
objective.
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most nuclei exhibited regular contours and were round
and large. The GS +DOX group showed slight DNA
condensation but only a few fragmentations of chroma-
tin. This suggests that apoptosis was the prevalent form
of cell death in H9C2 cells exposed to 1 μM of DOX. In
addition, we further measured the activity of caspase-3,Figure 9 Effects of GS on DOX-induced apoptosis using
caspase-3 activity assay in H9C2 cells. Subconfluent H9C2 cells
were treated with DOX and co-treated with different concentrations
of GS for 24 h, and caspase-3 activity was measured using
colorimetry. The results are expressed as mean±S.E. from 3
independent experiments. **P < 0.01 indicates a significant difference
from DOX treatment. ##P < 0.01 indicates a significant difference
from the control (GS 0 μM and DOX 0 μM).a major effector protein of apoptosis. As shown in
Figure 9, caspase-3 activity was increased by 1 μM of
DOX, and GS can inhibit DOX-induced caspase-3 ac-
tivity at 10–30 μM after 24 h of treatment.
GS did not interfere with DOX-induced cell death in
DLD-1 cells
To determine whether GS influences DOX in cancer
therapy, GS and DOX were combined to treat DLD-1
cells (human colon adenocarcinoma). As shown in
Figure 10A, the morphology of DLD-1 cells indicated
that they were injured after treatment with 1 μM of DOX;
however, GS (10, 20 and 30μM) did not reverse this re-
sponse. As shown in Figure 10B, GS (1–50 μM) did not
cause cytotoxicity in the DLD-1 cells. DOX (1 μM) can in-
duce 42.6% cell death; however, the cell viability did not
significantly increase after co-treatment of GS (1–50 μM)
and DOX. In addition, we assessed PARP, caspase-3, and
bax by Western blotting. As shown in Figure 10C, DOX
induced PARP and caspase-3 protein degradation, in-
creased cleaved-PARP and cleaved-caspase-3 expression,
and induced bax expression. However, these effects were
not influenced by co-treatment with GS.
Discussion
DOX, as an anthracycline antibiotic, has been used in
cancer therapy for nearly three decades. However, the
clinical use of DOX is restricted considerably by an
increased risk of cardiotoxicity associated with DOX-
Figure 10 Effects of combining GS and DOX in cancer cells. (A) Morphology of DOX-induced cell death. (B) Cell viability of the MTT assay.
(C) Western blotting of PARP, caspase-3 and bax protein expression in DLD-1 cells in the presence or absence of GS for 24 h. Images were
obtained with a 200× objective of the microscope. The assay methods were performed in the same manner as that described for the H9C2 cells.
Wang et al. BMC Complementary and Alternative Medicine 2012, 12:138 Page 8 of 10
http://www.biomedcentral.com/1472-6882/12/138induced cardiomyocyte apoptosis [27-29]. Adult car-
diomyocytes of the heart are well known to finally differ-
entiated muscle cells that do not progress proliferation
[30]. In addition, DOX seemed to affect specific enzymes
(NADH and FADH2), transporters (Ca
2+-ATPase and
Na+, and K+-ATPase), and metabolic pathways (AMP-
activated protein kinase) to varying extents in the cardiac
muscle. The accumulation of these defects may ultim-
ately result in irreversible cardiac failure [31]. This study
elucidated the protection of GS from DOX-induced
apoptosis and cell death by conducting the following
experiments: MTT assay, LDH release, DHE-staining,
fluorescence intensity of DCFH, lipid peroxidation,
Hoechst 33258 staining, caspase-3 activity measurement
and immunoblot analysis. The production of ROS as aderivative of the DOX metabolism has been suggested to
be the main mechanism of DOX-induced cardiotoxicity
[32-34]. However, superoxide radicals are involved in
other ROS and generate hydroxyl radical and hydrogen
peroxide [35]. According to current reports, generating
these ROS causes mitochondrial damage, which may lead
to cardiomyocyte apoptosis, necrosis, or death. In addi-
tion, these DOX-induced mitochondrial injuries in car-
diomyocytes were prevented by some natural substances,
such as curcumin, naringenin-7-O-glucoside, and plan-
tainoside D [20,36,37]. In our study, we used DCFH-DA
as an intracellular method of ROS detection [38]. The
results demonstrated that GS can significantly reduce the
intracellular ROS produced by DOX in H9C2 cells. We
also measured lipid peroxidation (MDA formation) in
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that GS can attenuate the oxidative stress induced by
DOX in H9C2 cells.
According to the identified apoptosis of cell signaling,
PARP is a nuclear enzyme activated by strand breaks in
DNA and implicated in DNA repair, apoptosis, organ
dysfunction, or necrosis [39,40]. In addition, it is known
that members of the bcl-2 protein family are known to
be major regulators of cytochrome C release and down-
stream caspases activation. Thus, bcl-2 plays a vital role
in regulating cardiomyocyte apoptosis [29,41]. Using
Western blot analysis, we found that GS treatment atte-
nuated DOX-induced apoptotic proteins (cleaved-PARP,
cleaved-caspase-3, and bax). In contrast, treatment with
GS also enhanced anti-apoptotic protein (bcl-2) expres-
sion in cardiomyocytes. Finally, another type of cancer
cell line, DLD-1, was used to exclude the possible inter-
ference of GS with DOX in cancer therapy. The data
showed that the efficacy of DOX did not diminish co-
treatment of GS and DOX.
Conclusion
Numerous studies have shown that myocardial impair-
ment caused by DOX may be due to cardiomyocyte
apoptosis, and DOX may also cause injury to endothelial
cells [42]. This study shows that GS is a novel potent
protector against DOX-induced cardiotoxicity, providing
protection using its antioxidative activity.
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